Login / Signup

Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

Yu-Tong WangLi BaoBin ChuXiao-Huan ChenMin-Qiu LuLei ShiShan GaoLi-Juan FangQiu-Qing XiangYue-Hua Ding
Published in: Journal of clinical laboratory analysis (2022)
The amp 1q21 predict inferior treatment response and survival, especially coexisted with high-risk IgH translocation.
Keyphrases
  • newly diagnosed
  • protein kinase
  • multiple myeloma
  • free survival